Therapeutic targeting of nuclear receptors, liver X and retinoid X receptors, for Alzheimer's disease

Abstract excerpt

After 15 years of research into Alzheimer's disease (AD) therapeutics, including billions of US dollars provided by federal agencies, pharmaceutical companies, and private foundations, there are still no meaningful therapies that can delay the onset or slow the progression of AD. An understanding of the proteolytic processing of amyloid precursor protein (APP) and the hypothesis that pathogenic mechanisms in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Alzheimer's disease research and treatments
• Share to Drug Transport and Resistance Mechanisms
• Share to Retinoids in leukemia and cellular processes